Navigation Links
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Date:6/1/2009

Ib study (previously disclosed as Study 204), 278 treatment naive, genotype 1 patients were randomized with the following patient demographics: mean age 48.8 yrs, 61.1% male, 30% African-American or Latino, 80.7% viral load >=400,000 IU/mL and 82.1 kg mean weight.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential for taribavirin in the treatment of hepatitis C, the continuing role of ribavirin or taribavirin in the treatment of hepatitis C and our ability to successfully pursue partnering opportunities for taribavirin, that are based on management's current expectations and involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the clinical development of new products, regulatory approval processes, that results from week 72 in the phase IIb clinical trial are not necessarily predictive of results in a phase III trial, our ability to successfully pursue partnering opportunities for taribavirin, and other risks as set forth under the caption Risk Factors in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated herein by reference. The company cautions the reader that these factors, as well as other factors described in its SEC filings, are among the factors that could cause actual results to differ materially from the expectations described in th
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DFB Sells Coria Labs to Valeant Pharmaceuticals
2. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
3. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... WASHINGTON D.C., April 15, 2014 -- According to ... danger to nuclear security comes from terrorists acquiring ... (HEU) to construct a crude nuclear explosive device. ... illicit nuclear trafficking have involved gram-level quantities, which ... methods. , According to a new study appearing ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2
... ChemAxon, a software,solutions provider for cheminformatics ... their cheminformatics toolkits, Marvin & JChem. The ... Markush enumeration and,core development in JChem search, ... JChem is a suite of application programming ...
... Feb. 19 NeurogesX, Inc.,(Nasdaq: NGSX ), ... therapies, announced today that it is scheduled to ... Growth Stock Conference in,Laguna Niguel, CA on February ... will be presenting and Stephen Ghiglieri, Chief,Financial Officer, ...
... Proprietary Technology Adopted in 16% of U.S. Cardiology ... ICG Acceptance and Clinical Importance, SAN DIEGO, ... leader of BioZ(R) impedance cardiography (ICG),technology, today announced ... American College of Cardiology,s ACCEL audio series., ...
Cached Biology Technology:ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance 2NeurogesX to Present at Roth 2008 OC Growth Stock Conference 2NeurogesX to Present at Roth 2008 OC Growth Stock Conference 3CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series 2CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series 3
(Date:7/10/2014)... 2014 Smart technology emphasis grows in ... improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... Apple Inc. (NASDAQ: AAPL ), Visa Inc. (NYSE: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... second series of 30 second spots on CNBC for its ...
(Date:7/10/2014)... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... Pereira was interviewed on July 1 st on ... . Mr. Pereira discusses the company,s next generation smart ... how the Wocket™ aims to replace a traditional wallet with ... Harris tells Gino he has never heard of the ...
(Date:7/10/2014)... Sweden , July 7, 2014 ... its first major design win (DW). A Chinese Top 5 ... the planned start of mass production in October 2014.   ... a Chinese Top 5 smartphone OEM, which has a planned ... and a target sales volume for this phone of 3 ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2